Phosphatidylserine and Prothrombin Antibodies, IgG and IgM
Ordering Recommendation
May be useful as an independent risk marker for thrombosis associated with APS and related diseases. Consider using when all criteria aPL antibody tests are negative; positive results should be reported to document persistence.
New York DOH Approval Status
Specimen Required
Serum separator tube (SST) OR lt. blue (sodium citrate)
Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum (Min: 0.3 mL) OR 0.5 mL citrate plasma (Min: 0.3 mL) to an ARUP standard transport tube.
Refrigerated. Also acceptable: Frozen.
Contaminated, heat-inactivated, clots, fibrin, gross red blood cells, severely lipemic, severely hemolyzed, or severely icteric specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Methodology
Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)
Performed
Thu
Reported
1-8 days
Reference Interval
Test Number |
Components |
Reference Interval |
---|---|---|
Phosphatidylserine and Prothrombin IgG | 0-30 Units | |
Phosphatidylserine and Prothrombin IgM | 0-30 Units |
Interpretive Data
The presence of elevated and persistent aPS/PT IgG and IgM antibodies (with or without lupus anticoagulant activity) may serve as a risk marker of thrombotic events in patients with certain autoimmune diseases, including antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). Strong clinical correlation is recommended for isolated IgM aPS/PT antibody.
FDA
Note
Hotline History
Hotline History
CPT Codes
83516 x2
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
2009448 | Phosphatidylserine and Prothrombin IgG | 85359-8 |
2009450 | Phosphatidylserine and Prothrombin IgM | 85358-0 |